Atrial Fibrillation – Epidemiology – Emerging Markets Data
Clarivate Epidemiology’s coverage of atrial fibrillation (AF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AF for each country, as well as annualized case counts projected to the national population. Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in the major pharmaceutical markets.
Clarivate Epidemiology’s AF forecast will answer the following questions:
- How will change in the levels of exposure to known risk or protective factors affect the number of people living with AF?
- Of all people with AF, how many in each country have been formally diagnosed?
- Of all people diagnosed with AF, how many in each of the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AF over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology provides at least 10 years of forecast data for the following AF patient populations:
- Total prevalent cases of AF.
- Diagnosed prevalent cases of AF.
- Undiagnosed prevalent cases of AF.
- Diagnosed prevalent cases of AF by subtype scheme.
- Diagnosed prevalent cases of AF by hypertension status.
- Diagnosed prevalent cases of AF by valvular heart disease status.
- Diagnosed prevalent cases of AF by heart failure status.
- Diagnosed prevalent cases of AF by NYHA subpopulation.
- Diagnosed prevalent cases of AF by CHADS2 score.
- Diagnosed prevalent cases of AF by CHA2DS2-VASc score.
- Diagnosed and drug-treated prevalent cases of AF.
- Diagnosed and non-drug-treated prevalent cases of AF.
- Diagnosed incident cases of AF.
… and many more (details available on request).
Note: Coverage may vary by country and region.
Table of contents
- Atrial Fibrillation - Epidemiology - Emerging Markets Data
- Introduction
- Key Findings
- Diagnosed Prevalence of Atrial Fibrillation per 1,000 People Aged 40+ in 2021
- Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Atrial Fibrillation Over the Next 10 yearstttttttt
- Analysis of Diagnosed Prevalent Cases of Atrial Fibrillation in the Countries Under Study in 2021 by Disease Subtypetttttttt
- Analysis of Diagnosed Prevalent Cases of Atrial Fibrillation in the Countries Under Study in 2021 With Comorbid Heart Failuretttttttt
- Analysis of Diagnosed Prevalent Cases of Atrial Fibrillation in the Countries Under Study in 2021 With Comorbid Hypertensiontttttttt
- Analysis of Diagnosed Prevalent Cases of Atrial Fibrillation in the Countries Under Study in 2021 With Comorbid Valvular Heart Diseasetttttttt
- Number of Additional Prevalent Cases of Atrial Fibrillation in 2031 in the Countries Under Study due to Trends in Obesitytttttttt
- Key Findings
- Epidemiology Data
- Methods
- Total Prevalent Cases
- Diagnosed Prevalent Cases
- Diagnosed Prevalent Cases by Subtype
- Atrial Fibrillation With Comorbid Heart Failure
- Atrial Fibrillation With Comorbid Hypertension
- Atrial Fibrillation With Comorbid Valvular Heart Disease
- Diagnosed Prevalent Cases of Atrial Fibrillation With Stroke Risk Based on CHADS2 Score
- Percentage Drug-Treated
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Atrial Fibrillation
- Studies Excluded From the Analysis of Atrial Fibrillation
- Risk/Protective Factors
- Risk/Protective Factors for Atrial Fibrillation
- Bibliography
- Abbreviations
- Glossary
- Literature Review
- Introduction
Utsav Patel, M.P.H., is an associate epidemiologist at Clarivate. His areas of interest are cardiovascular diseases and cancer epidemiology. Previously, he worked as a graduate research assistant at City University of New York, where he conducted multi-omics investigations into cancer study funded by the National Institutes of Health. He obtained his M.P.H. in epidemiology and biostatistics from City University of New York.
Alexandre Vo Dupuy, M.Sc., Pharm.D., is a principal epidemiologist at Clarivate. Previously, he worked in the fields of consulting and real-world evidence and at a major pharmaceutical company. He obtained his doctor of pharmacy from Descartes University in Paris and his master’s degree in pharmacoepidemiology from the University of Bordeaux. He has worked in multiple therapy areas, with a focus on cancer epidemiology. He also codeveloped a scenario-based forecast for COVID-19.